Dr. Anandkumar H. Singh, MBBS
Radiology (Diagnostic Radiology Physician)
Massachusetts General Hospital, 55 Fruit Street
Boston, MA 02114
- Medicare participating
At a glance
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 2,581
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Radiology Physician primary
MA license L-252949
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 2,581
- Services billed
- 3,672
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Ct scan head or brain without contrast | 297 | 293 |
| X-ray of chest, 1 view | 262 | 236 |
| Ct scan of abdomen and pelvis without contrast | 171 | 168 |
| Ct scan of abdomen and pelvis with contrast | 142 | 138 |
| X-ray of abdomen, 1 view | 137 | 128 |
| Ct scan of chest without contrast | 122 | 120 |
| Complete ultrasound scan behind abdominal cavity | 87 | 86 |
| Imaging of urinary tract following injection of a contrast agent | 71 | 61 |
| Ultrasound of leg arteries or artery grafts | 66 | 66 |
| Ct scan of blood vessels of neck with contrast | 64 | 64 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $18,100 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally A…
AstraZeneca UK Limited - Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie Inc. · Active, not recruiting · NCT05599984 - A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advance…
AstraZeneca UK Limited - A Modular Phase I IIa Open-label Multi-Centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tu…
AstraZeneca UK Limited - A Master Protocol of an Open-Label Multi-Drug Multi-Centre Phase II Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Immunogenicity of Novel Combinations in Participants with Locally Advanced Un…
AstraZeneca UK Limited - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. · Active, not recruiting · NCT02629159 - Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.